Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 11 Mar 2022 |
| Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022. | 10 Mar 2022 |
| Zealand Pharma convenes its Annual General Meeting 2022 | 10 Mar 2022 |
| Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022 | 25 Feb 2022 |
| Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI) | 15 Feb 2022 |
| Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome | 20 Jan 2022 |